BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects

Trial Information

BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects

BACKGROUND:

- Mutations in the BRCA1 and BRCA2 genes predispose to breast and ovarian cancer, and are
increasingly recognized in prostate and pancreatic cancers.

- Basal/ Triple negative breast cancer is associated with BRCA mutations in some
ethnicities.However the link between BRCA gene mutations and Basil/ triple negative
disease in Hispanic/ Latino women is not known.

- Common recurrent mutations in BRCA1 and BRCA2 exist in Hispanic/ Latino communities.

- New therapies such as PARP inhibitors may be particularly effective in BRCA mutation
carriers.

- Therefore a unique opportunity exists to identify women in this underserved minority
that may be eligible for and benefit from new targeted therapies.

OBJECTIVES:

- The primary objective is to collect saliva samples and histology data from up to 2000
Hispanic/ Latino subjects with breast cancer as a source of DNA, and to analyze the BRCA1
and BRCA2 genes..

ELIGIBILITY:

- All Hispanics females, over the age of 18, with breast cancer will be eligible.

DESIGN:

- Natural history study of 2000 Hispanic/Latino women with breast cancer, 1000 with triple

negative disease, 1000 without.

- Obtain clinical pathology reports and relevant history data on all subjects.

- Analyze recurrent BRCA1 and BRCA2 mutations